AUTIFONY THERAPEUTICS LIMITED
Get an alert when AUTIFONY THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£13M
-8.9% vs 2024
Net assets
£16M
-4.4% vs 2024
Employees
28
-9.7% vs 2024
Profit before tax
-£1.2M
-110.9% vs 2024
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-09-30
| Metric | Trend | 2023-09-30 | 2024-09-30 | 2025-09-30 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £1,369,894 | £19,315,793 | £4,110,165 | -78.7% | |
| Operating profit | -£5,663,004 | £10,302,911 | -£601,766 | -105.8% | |
| Profit before tax | -£5,616,644 | £10,632,320 | -£1,160,191 | -110.9% | |
| Net profit | -£4,693,204 | £10,743,550 | -£708,970 | -106.6% | |
| Cash | £4,512,821 | £14,739,323 | £13,432,992 | -8.9% | |
| Total assets less current liabilities | — | — | — | — | |
| Net assets | £5,618,187 | £16,350,489 | £15,634,938 | -4.4% | |
| Equity | £5,618,187 | £16,350,489 | £15,634,938 | -4.4% | |
| Average employees | 24 | 31 | 28 | -9.7% | |
| Wages | £1,972,206 | £2,465,910 | £1,954,069 | -20.8% | |
| Directors' remuneration | £920,102 | £380,765 | £364,208 | -4.3% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|---|
| Operating margin | — | 53.3% | -14.6% | |
| Net margin | — | 55.6% | -17.2% | |
| Gearing (liabilities / total assets) | 21.0% | 11.5% | 6.5% | |
| Current ratio | 4.78x | 8.49x | 15.01x | |
| Interest cover | — | — | -48.18x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- AUTIFONY THERAPEUTICS LIMITED 2011-06-01 → present
- NEWINCCO 1091 LIMITED 2011-02-25 → 2011-06-01
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting is appropriate. Based on the work performed, we have not identified any material uncertainties relating to events or conditions that may cast significant doubt on the group's or parent company's ability to continue as a going concern for at least 12 months from the date on which the financial statements are authorised for issue.”
Group structure
- AUTIFONY THERAPEUTICS LIMITED · parent
- Autifony Srl 100%
- Autifony Alpha Limited 100%
Significant events
- “During 2024-25 year, the company took the decision to divest the Italian wholly-owned subsidiary, Autifony Srl. Terms for this management buy-out were agreed and the divestment was concluded in May 2025. During 2025/26, Autifony will continue to explore a potential pharma partnership for the progression of AUT00206 into Phase II clinical trials in epilepsy or Fragile X Syndrome. The company will also progress the collaboration with Jazz towards the next milestones. The collaboration with Bl reached its second milestone as expected in early 2026 and an extension of the agreement has now been signed for a further 12 months, providing new income for Autifony. Over 2026, we expect to initiate new proprietary drug discovery programmes and at least one additional new collaboration.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| SELIN, Hannah Louise | Secretary | 2025-05-07 | — | — |
| AL-HALLAQ, Rana | Director | 2019-04-15 | Jun 1975 | American |
| BERRIMAN, John Edward | Director | 2011-05-23 | Apr 1948 | British |
| BINGHAM, Catherine Elizabeth, Dame | Director | 2011-08-19 | Oct 1965 | British |
| LARGE, Charles Henry | Director | 2011-05-23 | May 1967 | British |
| IP2IPO SERVICES LIMITED | Corporate Director | 2018-03-12 | — | — |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| OLSWANG COSEC LIMITED | Corporate Secretary | 2011-02-25 | 2011-05-23 |
| ALVARO, Giuseppe | Director | 2011-05-23 | 2011-08-19 |
| BAXTER, Allan | Director | 2011-08-19 | 2015-01-27 |
| BHAMAN, Maina | Director | 2011-08-19 | 2017-12-15 |
| JONES, Elaine, Dr | Director | 2013-02-14 | 2019-04-15 |
| MACKIE, Christopher Alan | Director | 2011-02-25 | 2011-05-23 |
| PANDE, Atul Chandra, Dr | Director | 2014-04-01 | 2024-01-31 |
| SONI, Bobby G., Dr | Director | 2017-12-15 | 2018-03-12 |
| OLSWANG DIRECTORS 1 LIMITED | Corporate Director | 2011-02-25 | 2011-05-23 |
| OLSWANG DIRECTORS 2 LIMITED | Corporate Director | 2011-02-25 | 2011-05-23 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Pfizer Inc | Corporate entity | Shares 25–50% | 2021-11-01 | Ceased 2023-01-12 |
| Svls Life Sciences Fund V Lp | Corporate entity | Shares 25–50% | 2016-04-06 | Ceased 2021-11-01 |
| Touchstone Innovations Businesses Llp | Corporate entity | Shares 25–50%, Voting 25–50% | 2016-04-06 | Active |
Filing timeline
Last 20 of 139 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-10-17 RESOLUTIONS Resolution
- 2024-06-28 MA Memorandum articles
- 2024-06-28 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-24 | AA | accounts | Accounts with accounts type group | |
| 2026-03-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-03-20 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-03-03 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2025-10-17 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2025-10-17 | SH20 | capital | Legacy | |
| 2025-10-17 | CAP-SS | insolvency | Legacy | |
| 2025-10-17 | RESOLUTIONS | resolution | Resolution | |
| 2025-06-13 | AA | accounts | Accounts with accounts type group | |
| 2025-05-07 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-03-04 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-07-29 | SH01 | capital | Capital allotment shares | |
| 2024-07-29 | SH01 | capital | Capital allotment shares | |
| 2024-07-02 | AA | accounts | Accounts with accounts type group | |
| 2024-06-28 | MA | incorporation | Memorandum articles | |
| 2024-06-28 | RESOLUTIONS | resolution | Resolution | |
| 2024-03-05 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-02-27 | SH01 | capital | Capital allotment shares | |
| 2024-02-08 | TM01 | officers | Termination director company with name termination date | |
| 2023-11-23 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 4
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.